SereNeuro Therapeutics, a preclinical-stage biotechnology company developing non-opioid therapies for pain, announced the close of its oversubscribed pre-seed financing. The round advances the company's lead program, SN101, toward Investigational New Drug (IND)-enabling activities and supports its second program, SN102.